Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

Excessive sugar consumption may contribute to male pattern hair loss by increasing androgen sensitivity and insulin resistance, but genetics play a significant role. Treatments like minoxidil and finasteride are suggested for managing hair loss, while reducing sugar intake and maintaining a healthy lifestyle may help mitigate its progression.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

The user has been using finasteride for over a year without improvement and recently started oral minoxidil. Suggestions include trying dutasteride and continuing minoxidil for potential regrowth.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

High dose topical Finasteride solutions are speculative and not proven more effective than low dose solutions. Users report varying results with different concentrations, with some preferring lower doses to minimize side effects.

The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

A user experienced dry, brittle hair after starting dutasteride and considered switching back to finasteride. Another user advised that the dryness is temporary and shared positive results with dutasteride and oral minoxidil after several months.

The user has been using finasteride and ketoconazole for hair loss and is considering changing shampoos due to dryness caused by ketoconazole. Responses suggest that stopping ketoconazole won't affect hair loss unless the user has seborrheic dermatitis, and recommend using conditioner or using ketoconazole shampoo less frequently.

Oral minoxidil may cause dry skin and dark eye bags but doesn't significantly age the skin. Topical minoxidil is toxic to cats, and some users prefer finasteride.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

A user shared their positive experience with hair regrowth after 3 months of using 6% Minoxidil and 0.3% Finasteride spray. They experienced temporary erectile dysfunction but it resolved, although morning erections are less frequent.

User discusses resentment towards people who dismissed their hair loss concerns and continued to do so even after a specialist confirmed it. Others share similar experiences and discuss the impact of hair loss on self-esteem and societal perceptions.

Hair loss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.

A user's experience of slowing hair loss while taking minoxidil and finasteride, and the various treatments suggested to help halt or reverse the process.

A user shared their hair loss treatment plan using Revita tablets, Sulforaphane, Minoxidil, and microneedling, avoiding finasteride due to side effects. Replies suggest that without finasteride, the plan is unlikely to be effective, and recommend either using finasteride or shaving their head.

The availability of Topical Dutasteride, a potential treatment for hair loss, which can be purchased without prescription from MinoxidilMax. Other treatments discussed include Topical Finasteride and PRP injections, with discussion around dosage, efficacy, side-effects and safety.

A user who has had positive results from using a regimen of microneedling, finasteride, minoxidil, peppermint oil, keto shampoo and DHT organic shampoo for hair growth. The conversation also addressed whether to use .5mg or 1mg of finasteride and the difference between dermapens and rollers.